ReviewKidney3602025
BK Nephropathy in the Modern Era: What Have We Learned?
Review in Kidney360, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BK polyomavirus (BKPyV) remains a significant cause of graft dysfunction and failure in kidney transplant recipients, with DNAemia affecting up to 30% and nephropathy contributing to approximately 7% of graft losses. This review synthesizes current understanding of BKPyV pathogenesis, risk factors, and management strategies. Screening protocols and immunosuppression reduction remain the cornerstone of care, although emerging therapies-including monoclonal antibodies and virus-specific T-cell therapies-offer promise. The role of mammalian target of rapamycin inhibitors and other agents is critically evaluated, with recent trials challenging their efficacy. Unique transplant-related factors, such as ureteral stent use and the kidney's role as a viral reservoir, may explain the predominance of BKPyV in renal transplantation. This review highlights the need for improved serologic and cellular immunity assays, targeted antiviral therapies, and individualized approaches to retransplantation. Continued research is essential to reduce the burden of BKPyV-associated nephropathy and improve long-term kidney transplant outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.